{"id":"abb-r-chop","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Infection"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4069217","moleculeType":"Small molecule","molecularWeight":"640.68"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It combines the anti-CD20 monoclonal antibody rituximab with the chemotherapy agents cyclophosphamide, doxorubicin, vincristine, and prednisone. This combination works by inducing cell death in rapidly dividing cancer cells, such as those found in non-Hodgkin lymphoma.","oneSentence":"Abb-R-CHOP is a combination chemotherapy regimen that targets rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:10.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT03399747","phase":"PHASE2","title":"Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2016-12-07","conditions":"Diffuse Large B-cell Lymphoma","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Abb-R-CHOP","genericName":"Abb-R-CHOP","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abb-R-CHOP is a combination chemotherapy regimen that targets rapidly dividing cancer cells. Used for Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}